Preparation method of composition for ovarian transplantation and composition
By combining the antioxidant peptide SS31 with the colony stimulating factor GM-CSF, the problem of follicle loss in frozen and thaw transplantation of ovarian tissue was solved, the survival rate and transplant effect of follicles were improved, and higher fertility protection was achieved.
Patent Information
- Application Number
- CN202410998845.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-24
AI Technical Summary
During the frozen and freeze-thaw transplantation of existing ovarian tissues, follicles suffer serious losses during ischemia and reperfusion, mainly because the antioxidant vitamin E is difficult to reach the ROS production site in the mitochondria, resulting in poor antioxidant effect.
Using a composition containing antioxidant peptide SS31 and colony stimulating factors (such as GM-CSF), by attaching the antioxidant peptide to the colony stimulating factors, ensuring that it can exist stably in the blood, reaching the ROS production site, and attenuating ROS production. the reactive oxygen species improves the survival rate of follicles.
It significantly reduces the apoptosis rate of follicles, improves the effect of frozen-thaw ovarian tissue transplantation, and increases the survival rate and number of follicles after transplantation.
Smart Images

Figure CN118924880A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of peptides, and in particular to a preparation method and a composition for ovarian transplantation. Background Art
[0002] Currently, the number of new patients with malignant tumors is increasing, among which the proportion of female patients under 30 years old is increasing. Given that most young patients still retain the desire to have children, and cytotoxic drugs and radiotherapy in tumor treatment may seriously damage their fertility and even cause premature ovarian insufficiency, fertility protection and preservation are particularly important for these patients. Among the existing methods of preserving female fertility, ovarian tissue freezing has become the best choice for young patients with malignant tumors to preserve fertility because it does not require ovulation pretreatment and can immediately protect the patient's endocrine function and fertility. At present, there have been more than 200 cases of successful live births through ovarian tissue freezing technology worldwide.
[0003] Although there are still some technical limitations of ovarian tissue freezing methods, the main issue that determines the survival of ovarian tissue is that during the frozen-thaw ovarian tissue transplantation process, since ovarian cortical fragments without vascular anastomosis are usually used for transplantation, the graft will experience ischemia and hypoxia for several days in the early stage before the establishment of new blood vessels, resulting in the loss of about 50%-90% of primordial follicles during the ischemia-reperfusion process after transplantation.
[0004] Currently, during frozen-thawed ovarian tissue transplantation, the antioxidant vitamin E is injected locally before transplantation. Vitamin E can reduce the generation sites of reactive oxygen species (ROS) in mitochondria and improve the survival rate of follicles. However, the permeability of primordial follicles is poor, and it is difficult for vitamin E to reach the generation sites of ROS in mitochondria, so its antioxidant effect is poor, resulting in the loss of follicles during the ischemia-reperfusion process after transplantation. Summary of the invention
[0005] The present invention aims to solve the problem of poor antioxidant effect of vitamin E in the process of frozen-thawed ovarian tissue transplantation in the prior art, and provides a novel composition comprising antioxidant peptides and colony stimulating factors. In the composition, the antioxidant peptides are attached to the colony stimulating factors to ensure that the antioxidant peptides can reach the ROS site. The antioxidant peptides can remove the reactive oxygen generated by the ROS site and weaken the ability of the ROS site to generate oxygen, thereby improving its antioxidant effect, reducing follicle loss, thereby protecting more follicles, and ultimately improving the effect of frozen-thawed ovarian tissue transplantation.
[0006] The technical method of the present invention is as follows:
[0007] A composition for ovarian transplantation, comprising antioxidant peptides and colony stimulating factors.
[0008] The colony stimulating factor is selected from any one of macrophage colony stimulating factor, granulocyte macrophage colony stimulating factor and granulocyte colony stimulating factor.
[0009] Furthermore, the ratio of colony stimulating factor to antioxidant peptide is 1 mL: 10-100 mg.
[0010] Furthermore, the ratio of colony stimulating factor to antioxidant peptide is 1 mL:50 mg.
[0011] The antioxidant peptide is SS31.
[0012] Furthermore, the composition comprises granulocyte macrophage colony stimulating factor and SS31.
[0013] The present invention also provides a method for preparing the above composition, which comprises fusing the antioxidant peptide and the colony stimulating factor to prepare the composition.
[0014] The fusion time is 30 to 40 minutes.
[0015] The present invention provides use of the composition in ovary transplantation.
[0016] The present invention provides the above composition using rhodamine for tracing.
[0017] The present invention has the following beneficial effects:
[0018] The antioxidant peptides in the composition of the present invention are attached to the colony stimulating factor, ensuring that the antioxidant peptides can reach the ROS site. The antioxidant peptides can remove the active oxygen generated by the ROS site and weaken the ability of the ROS site to generate oxygen, thereby improving its antioxidant effect and reducing follicle loss, thereby protecting more follicles and ultimately improving the effect of frozen-thawed ovarian tissue transplantation. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 A diagram showing a method for preparing the composition;
[0020] Figure 2 is a tracer diagram of the composition;
[0021] Figure 3 This is the fluorescence signal diagram of 10 mg of SS31;
[0022] Figure 4 This is the fluorescence signal diagram of 30 mg of SS31;
[0023] Figure 5 This is the fluorescence signal diagram of 50 mg of SS31. DETAILED DESCRIPTION
[0024] At present, the possible mechanisms of follicle loss after ovarian tissue cryotransplantation include: (1) apoptosis mechanism: mitochondrial damage caused by oxidative stress during ovarian tissue cryotransplantation induces cell apoptosis through the mitochondrial pathway; (2) overactivation mechanism: quiescent primordial follicles are overactivated and enter the growth stage, causing "explosive growth" of primordial follicles in a short period of time, followed by atresia of most follicles, resulting in premature depletion of the follicle reserve pool.
[0025] In order to solve the problem of primordial follicle withering during freezing or transplantation, the inventors tried to add antioxidants to the vitrification freezing solution, and found that adding SS31 can improve the effect of ovarian vitrification cryopreservation to a certain extent. SS31 (HD-Arg-Dmt-Lys-Phe-NH) is a new type of mitochondrial targeted antioxidant peptide, belonging to the family of small molecule cell-permeable peptides. It can target and aggregate in the inner membrane of mitochondria, selectively bind to cardiolipin, and accumulate 1000 to 5000 times in mitochondria. Mitochondrial uptake of SS31 is not dependent on mitochondrial transmembrane potential. However, although adding SS31 to the vitrification freezing solution can improve the freezing effect of ovaries to a certain extent, the effect is not very ideal.
[0026] The inventors also tried to study the effect of SS31 on the frozen-thawed ovarian tissue by intraperitoneal injection of SS31 (5 mg / kg / day). The results showed that SS31 could improve the transplantation effect to a certain extent, but the effect was still not obvious. It is speculated that the possible reason is that SS31, as an active peptide drug, has a short half-life, is unstable in the blood circulation, and is easily enzymatically hydrolyzed, resulting in low bioavailability, thus affecting the maintenance of SS31's antioxidant stress effect.
[0027] In order to improve the bioavailability of SS31, the inventors used a combination of SS31 and human granulocyte-macrophage colony-stimulating factor (GM-CSF) for ovarian tissue transplantation and found that the combination could significantly reduce the apoptosis rate of ovarian follicles.
[0028] Therefore, the present invention provides a composition for ovarian transplantation, comprising an antioxidant peptide and a colony stimulating factor. Here, the antioxidant peptide is located on a colony stimulating factor carrier, and during the transplantation process, the colony stimulating factor can enable the antioxidant peptide to be stably present in the blood circulation and is not easily enzymatically degraded.
[0029] In some specific embodiments of the present invention, the colony stimulating factor is selected from any one of macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and granulocyte colony stimulating factor (G-CSF). Here, M-CSF, M-CSF, and G-CSF are small molecule proteins or polypeptides produced by cells and secreted outside the cells, which can regulate the growth, differentiation, survival, or function of other cells. Such small molecule proteins or polypeptides can maintain the stability of blood and respond to external stimuli (such as infection, trauma, etc.), thereby ensuring that the antioxidant peptides can be stably present at the transplant site, so that the antioxidant effect can continue to be exerted during the ischemia-reperfusion period after ovarian transplantation.
[0030] Preferably, the colony stimulating factor is granulocyte macrophage colony stimulating factor. Here, GM-CSF can act on a variety of cell types, especially macrophages and eosinophils, and has a wider range of immunomodulatory effects, so the harm to the human body through the GM-CSF carrier is small.
[0031] In some specific embodiments of the present invention, the antioxidant peptide is SS31. Specifically, S31 is a new type of mitochondrial targeted antioxidant peptide, which can be targeted to the inner membrane of mitochondria, selectively bind to cardiolipin, and can accumulate 1000 to 5000 times in mitochondria. SS31 can directly remove reactive oxygen at the site of reactive oxygen production, and bind to cardiolipin in the inner membrane of mitochondria through electrostatic and hydrophobic interactions, thereby protecting mitochondrial function, improving the efficiency of mitochondrial electron transfer, and reducing the ability of ROS production in mitochondria. SS31 can also inhibit the mitochondrial permeability transition pore (mPTP), reduce the production of ROS in mitochondria, and prevent mitochondrial swelling.
[0032] Preferably, the composition comprises granulocyte macrophage colony stimulating factor and SS31.
[0033] Optionally, the ratio of colony stimulating factor to antioxidant peptide is 1 mL: 10-100 mg. For example, the ratio of colony stimulating factor to antioxidant peptide can be 1 mL: 20 mg, 1 mL: 50 mg, 1 mL: 80 mg.
[0034] In some specific embodiments of the present invention, the composition is semisolid. Here, 1 mL of colony stimulating factor gel contains 10 to 100 mg of antioxidant peptide.
[0035] In the present invention, the composition may further contain a carrier or an excipient.
[0036] "Carrier" or "excipient" as used herein includes any and all solvents, diluents, buffers (e.g., neutral buffered saline or phosphate buffered saline), solubilizers, colloids, dispersion media, carriers, fillers, chelating agents (e.g., EDTA or glutathione), amino acids (e.g., glycine), proteins, disintegrants, adhesives, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, aromatics, thickeners, agents for obtaining a depot effect, coatings, antifungal agents, preservatives, stabilizers, antioxidants, osmotic control agents (tonicity controlling agent), absorption delay agents, etc. The use of these media and agents in pharmaceutically active substances is well known in the art. These materials are compatible with other ingredients and harmless to their receptors.
[0037] like Figure 1 As shown, GM-CSF is fused to SS31, and SS31 is attached to the GM-CSF vector.
[0038] The present invention also provides a method for preparing the composition, which comprises fusing the antioxidant peptide and the colony stimulating factor to prepare the composition.
[0039] The fusion temperature is 30 to 40° C. For example, the temperature is 37° C.
[0040] The present invention also provides a use of the above composition, wherein the composition is used for ovarian transplantation, and the use may also include ovarian cryopreservation.
[0041] Here, the composition acts on the site of ovarian transplantation. Specifically, SS31 / GM-CSF significantly increased the number of new blood vessels at the interface of ovarian tissue transplantation, suggesting that GM-CSF gel has the effect of promoting angiogenesis. The MDA content in the grafts of the SS31 / GM-CSF group decreased significantly 3 and 7 days after transplantation, suggesting that the oxidative stress level of the SS31 / GM-CSF group decreased in the early stage after transplantation. Histological examination intuitively shows that the survival rate of the grafts in the SS31 / GM-CSF group is higher, and most importantly, the number of primordial follicles retained in the grafts is significantly increased. Secondly, the study found that the mechanism by which SS31 improves graft survival is related to SS31 inhibiting p66Shc phosphorylation, reducing mitochondrial dynamics damage, reducing cytochrome C release and ROS generation, and maintaining intracellular energy metabolism during the freezing process.
[0042] The present invention also provides a tracing method for the above composition, wherein the composition is traced by rhodamine. The tracing step comprises: mixing an antioxidant peptide (eg, SS31) with rhodamine, then adding colony stimulating factor to mix, obtaining a composition, and using the composition to detect ovarian transplantation.
[0043] Here, the ovaries can also be stained.
[0044] The present invention is further described in detail below through specific implementation cases and accompanying drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. After reading the present invention, various equivalent forms of modifications to the present invention by those skilled in the art are all within the scope of the claims attached to this application.
[0045] Unless otherwise specified, the culture media, reagents and solutions used in the following examples are commercially available or can be prepared by methods known in the art.
[0046] Example 1 Rhodamine-SS31 tracer analysis
[0047] 1. HE staining
[0048] Five ovarian tissue samples in each group were fixed with 4% paraformaldehyde and embedded in paraffin.
[0049] (1) Dewaxing: Bake the embedded paraffin sections at 60°C for 1 hour, then place them in xylene twice, soaking for 20 minutes each time.
[0050] (2) Rehydration: Place the sections in 100%, 100%, 95%, 85%, and 75% alcohol gradients for 5 minutes each time, and finally place them in PBS.
[0051] (3) Staining: The rehydrated paraffin sections were sliced into 4 μm sections, and one section was selected every three sections. The sections were stained with HE and sealed with neutral gum.
[0052] (4) Observation and counting: Observe under an optical microscope and grade according to Gougeon's follicle grading criteria: Primordial follicle: oocytes are surrounded by a single layer of flat granulosa cells; Primary follicle: oocytes are surrounded by a single layer of cuboidal granulosa cells; Secondary follicle: oocytes are surrounded by two or more layers of cuboidal granulosa cells, without an antral cavity; Antral follicle: oocytes are surrounded by two or more layers of cuboidal granulosa cells, with an antral cavity. The classification of follicle morphological defects is determined according to Neto's classification criteria: Type I: no morphological defects, regular follicles and surrounding granulosa cells, and uniform distribution of oocyte cytoplasm; Type II: abnormal oocyte cytoplasm, cytoplasmic vacuolar degeneration or eosinophilia; Type III: abnormal oocyte nucleus, shrunken nucleus, irregular or missing nuclear membrane; Type IV: degenerated follicles, abnormal follicle morphology or granulosa cells, abnormal oocyte cytoplasm and nucleus. Because the number of primary and secondary follicles in the rabbit ovarian tissue was too small in this experiment, the primary and secondary follicles were uniformly classified as growing follicles. Considering the importance of primordial follicles in ovarian tissue freezing and transplantation, only the normal morphological rate of primordial follicles was counted. This part of the content was read by two experienced pathologists and the author himself. Under a 200x optical microscope, different sections of 3 samples were selected for observation in each group. 10 fields of view were randomly selected from each section for primordial follicle counting, and the average number of primordial follicles in each field of view was calculated. The morphological defects of the primordial follicles were determined under a 400x optical microscope, that is, the proportion of Type I primordial follicles to the total number of primordial follicles. To avoid repeated counting, only primordial follicles with visible oocyte nuclei were counted.
[0053] 2. Transmission electron microscopy of ovarian tissue
[0054] Three ovarian tissue samples in each group were used for transmission electron microscopy.
[0055] (1) Fixation: Ovarian tissue was pre-fixed with 3% glutaraldehyde and then re-fixed with 1% osmium tetroxide.
[0056] (2) Dehydration: Dehydration with acetone step by step, the concentration gradient of the dehydrating agent is 30% → 50% → 70% → 80% → 90% → 95% → 100% (100% concentration was changed 3 times).
[0057] (3) Infiltration and embedding: The ratios of dehydrating agent and Epon812 embedding agent were 3:1, 1:1, and 1:3, respectively, and finally Epon812 embedding.
[0058] (4) Ultrathin sectioning: Use an ultrathin microtome to prepare ultrathin sections of approximately 60 to 90 nm, spread the sections, and then scoop them onto a copper mesh.
[0059] (5) Staining: First stain with uranyl acetate for 10 to 15 minutes, then stain with lead citrate for 1 to 2 minutes, and stain at room temperature.
[0060] (6) Observation and counting: A transmission electron microscope was used to collect images of the copper grid and observe the ultrastructure of the oocytes, granulosa cells and their intracellular organelles in the primordial follicles. The mitochondrial morphology in the oocytes and granulosa cells was determined. The criteria for determining mitochondrial morphology were as follows: normal mitochondrial structure was complete, with complete parallel cristae and uniform matrix density; abnormal mitochondrial shape was more heterogeneous, with mitochondrial swelling, mitochondrial outer membrane rupture, and mitochondrial cristae structure breakage and disappearance. The mitochondrial structure in the oocytes and granulosa cells of the primordial follicles was observed at 13,000 times and identified based on mitochondrial ultrastructural damage. Three samples were observed in each group, and the mitochondrial structure of the oocytes and granulosa cells in four primordial follicles was randomly observed in each group. At least 10 mitochondria in five areas of each follicle were randomly observed to calculate the abnormal mitochondrial ratio.
[0061] 3. Immunohistochemical detection of TUNEL staining of ovarian tissue
[0062] (1) Dewaxing: sequentially place the sections in xylene I for 10 min, xylene II for 10 min, xylene II for 10 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, anhydrous ethanol III for 5 min, and wash with distilled water.
[0063] (2) Proteinase K repair: After the slices are slightly dried, use a tissue pen to draw a circle around the tissue (to prevent the liquid from flowing away), add proteinase K working solution to the circle to cover the tissue, and incubate in a 37°C incubator for 22 minutes. Place the slide in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, each time for 5 minutes. (Protease K working solution preparation method, stock solution: PBS = 1:9).
[0064] (3) Membrane permeabilization: After the slices are slightly dried, add a drop of membrane permeabilization working solution in the circle to cover the tissue, incubate at room temperature for 20 minutes, place the slides in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, each time for 5 minutes. (The membrane permeabilization solution is 0.1% triton. Preparation method, triton stock solution: PBS = 1:1000).
[0065] (4) Room temperature equilibrium: After the slices are slightly dried, add buffer to cover the tissue and incubate the buffer at room temperature for 10 min.
[0066] (5) Add reaction solution: According to the number of slices and tissue size, take an appropriate amount of TDT enzyme, dUTP, and buffer in the tunel kit in a ratio of 1:5:50, add it to the circle to cover the tissue, place the slices flat in a humidified box, incubate at 37°C for 2 h, and add a small amount of water to the humidified box to maintain humidity.
[0067] (6) Add substrate: Add 50-100 μl DAB substrate to the tissue and react for 10 min (15-25°C); rinse with PBS three times.
[0068] (7) Restaining: Restain with hematoxylin, rinse immediately with deionized water after a few seconds, and seal the slide with neutral gum.
[0069] (8) Observation and counting: Observe, count and take photos under an optical microscope. Oocyte apoptosis is manifested by a clear brown-yellow or brown-brown oocyte nucleus and a purple-blue background. Each slice is marked with the oocyte nucleus at a 200x field of view. Ten fields of view are randomly selected to count the total number of oocytes and the number of apoptotic oocytes, and the oocyte apoptosis rate is calculated.
[0070] 4. Immunofluorescence detection of TUNEL staining of ovarian tissue
[0071] Steps (1) to (5) are the same as (1) to (5) in immunohistochemical detection of TUNEL staining of ovarian tissue.
[0072] (6) DAPI counterstaining of cell nuclei: Wash the sections with PBS (pH 7.4) three times, 5 min each time. After removing the PBS, add DAPI staining solution to the circle and incubate at room temperature for 10 min away from light.
[0073] (7) Sealing: Place the slides in PBS (pH 7.4) and wash them on a decolorizing shaker for 3 times, 5 min each time. Slightly spin dry the sections and seal them with an anti-fluorescence quenching sealing medium.
[0074] (8) Microscopic examination and photography: The sections were observed and images were collected under a fluorescence microscope. (DAPI has an ultraviolet excitation wavelength of 330-380 nm, an emission wavelength of 420 nm, and emits blue light; FITC has an excitation wavelength of 465-495 nm, an emission wavelength of 515-555 nm, and emits green light.
[0075] (9) Result determination: The cell nuclei stained with DAPI are blue under ultraviolet excitation, and the positive apoptotic cell nuclei are green when the kit is labeled with FITC fluorescence. Different sections of 3 samples were selected for observation in each group, and 5 fields of view were randomly selected from each section for photography. The total number of positively stained cells and interstitial cells were counted using Image J software. The ratio of TUNEL-positive interstitial cells to the total number of interstitial cells was calculated.
[0076] 5. Establishment of a GM-CSF gel-loaded SS31 and ovarian tissue co-transplantation model
[0077] First, SS31 (rhodamine-SS31) with a fluorescent label was synthesized, and then co-transplanted with rhodamine-SS31 and ovaries for in vivo detection to confirm the tracing effect of rhodamine-SS31. 50 mg of rhodamine-SS31 was mixed with the gel and then transplanted with fresh ovarian cortex fragments on the right side, while the left ovary was used as a control without any treatment. In vivo imaging detection was performed immediately after surgery. Figure 2 As shown in the figure, it can be observed through in vivo imaging that the fresh ovary transplantation site on the right side of the rabbit presents obvious fluorescent signals, while the left control site has no fluorescent signals. The results clearly show that rhodamine-SS31 can be traced by in vivo imaging detection.
[0078] 6. Rhodamine-SS31 tracer analysis
[0079] To confirm the tracing effect of rhodamine-SS31, in vivo imaging was performed 3 days after co-transplantation of gels loaded with different doses of rhodamine-SS31 and fresh ovarian cortex fragments. Figure 3 , 4 As shown in Figure 5, when 10 mg of SS31 was loaded, almost no fluorescence signal was detected 3 days after surgery; when 30 mg of SS31 was loaded, a weak fluorescence signal was visible 3 days after surgery; and when 50 mg of SS31 was loaded, a stronger fluorescence signal was visible 3 days after surgery, indicating that 50 mg of SS31 has better performance.
[0080] Example 2 Preparation of composition
[0081] (1) 50 mg of SS31 was fully mixed with 1 mL of GM-CSF gel to prepare an SS31 gel composition.
[0082] (2) Use ophthalmic scissors to gently scrape the surface of the retroperitoneum of the female rabbit's pelvis, and create a wound of about 2 cm × 2 cm in size at the retroperitoneum of the ovary in situ; apply the SS31 and GM-CSF gel composition evenly on the wound (the length and width of the application are both larger than the wound, and the application thickness is about 1 mm, to form a transplant "bed" structure).
[0083] (3) Two pieces of fresh ovarian cortical fragments (1-1.5 cm long, 0.3-0.5 cm wide, and 1 mm thick) were adhered to the surface of the SS31 gel composition, and two stitches (one at each end) of 6-0 silk thread were used to fix the ovarian tissue to complete the transplantation operation; the rabbit's abdominal skin was sutured, the incision was disinfected, and the rabbit was placed on a warming pad until it woke up from anesthesia.
[0084] Comparative Example 1: Conventional frozen-thawed ovarian tissue transplantation group (OT group)
[0085] (1) Use ophthalmic scissors to gently scrape the surface of the female rabbit's pelvic retroperitoneum, and create a wound of about 2 cm × 2 cm in size at the retroperitoneum of the ovary in situ; apply the smear evenly on the wound (the length and width of the smear are both larger than the wound, and the smear thickness is about 1 mm, to form a transplant "bed" structure).
[0086] (2) Two pieces of fresh ovarian cortical fragments (1-1.5 cm long, 0.3-0.5 cm wide, 1 mm thick) were adhered to the peritoneal surface and sutured with two stitches of 6-0 silk thread (one at each end) to fix the ovarian tissue and complete the transplantation operation; the rabbit's abdominal skin was sutured, the incision was disinfected, and the rabbit was placed on a warming pad until it woke up from anesthesia.
[0087] Comparative Example 2 OT (frozen-thawed ovarian tissue) and GM-CSF
[0088] (1) Use ophthalmic scissors to gently scrape the surface of the retroperitoneum of the female rabbit's pelvis, and create a wound of approximately 2 cm × 2 cm in size at the retroperitoneum of the ovary in situ; apply GM-CSF gel evenly on the wound (the length and width of the application are both larger than the wound, and the application thickness is approximately 1 mm, to form a transplant "bed" structure).
[0089] (2) Two pieces of fresh ovarian cortical fragments (1-1.5 cm long, 0.3-0.5 cm wide, 1 mm thick) were adhered to the peritoneal surface and sutured with two stitches of 6-0 silk thread (one at each end) to fix the ovarian tissue and complete the transplantation operation; the rabbit's abdominal skin was sutured, the incision was disinfected, and the rabbit was placed on a warming pad until it woke up from anesthesia.
[0090] Transplantation effect evaluation
[0091] The transplantation effect was evaluated by Example 2, Comparative Example and Comparative Example 2. The HE staining and Tunel immunofluorescence staining of the grafts 7 days after transplantation in Example 1 were performed to statistically analyze the primordial follicle density and the apoptosis rate of primordial follicles in each group after ovarian tissue transplantation.
[0092] The results showed that the primordial follicle density of SS31 / GM-CSF+OT was 40.50±4.95 per unit area, which was significantly higher than that of the OT group (6.00±1.14) and the GM-CSF+OT group (11.00±2.83), and the difference was statistically significant (P<0.05). There was no significant difference in the primordial follicle density between the OT group and the GM-CSF+OT group (P>0.05).
[0093] The apoptosis rate of primordial follicles in the OT group (0.41±0.02) was significantly higher than that in the SS31 / GM-CSF+OT group (0.10±0.012) and the GM-CSF+OT group (11.00±2.83), and the difference was statistically significant (P<0.05). The experimental results showed that in fresh ovarian transplantation, GM-CSF gel carrying SS31 can improve the effect of ovarian cortex autotransplantation, and the gel-carrying SS31 and ovarian tissue co-transplantation model was successfully established.
[0094] In order to determine the effect of SS31 on the early effects of frozen-thawed ovarian tissue transplantation, we used the gel-loaded SS31 transplantation model established in the previous experiment to perform rabbit frozen-thawed ovarian autologous orthotopic transplantation. Experimental index detection was performed at two time points, 3 days and 7 days after transplantation, for Example 2, Comparative Example 1 and Comparative Example 2.
[0095] Three days and seven days after transplantation, five rabbits in each group were selected for laparotomy to observe the grafts, and the grafts were obtained for HE staining. After frozen-thawed ovarian tissue transplantation in each group, the ovarian grafts were in place and the tissue did not fall off. Macroscopic observation showed that the boundaries between the ovarian tissue and the surrounding tissues were clear three days after transplantation, and the tissue had basically fused completely with the tissue at the transplant site; it was seen that some grafts were arched in whole or in part, with loose connection and poor fusion with the transplant site below, and the tissue color was dark brown, indicating that the graft was partially or completely necrotic. Seven days after transplantation, the boundaries between the ovarian tissue and the transplant site were unclear, and it was tightly fused with the tissue below and difficult to separate. The tissue color was similar to that of the surrounding tissue, indicating that the ovarian tissue graft survived. However, some grafts were partially dark brown and arched, indicating that the graft was partially necrotic.
[0096] The grafts were stained with HE, and the survival of the grafts was determined based on the tissue morphology. The cell nuclei of the surviving grafts were stained normally, and the primordial follicles were visible. In the non-surviving grafts, the cell nuclei of the whole tissue were deeply stained, the cells were apoptotic, and no follicles remained. Thus, the survival of the ovarian grafts in each group was counted. The results are shown in Table 1. The results show that the survival rate of the ovarian tissue transplantation in Example 2 is the highest.
[0097]
[0098] Table 1
[0099] Calculation of primordial follicle density 3 days and 7 days after transplantation
[0100] Based on the morphological changes in the early tissue sections after frozen-thawed ovarian tissue transplantation, in which no growing follicles survive, the number and status of primordial follicles remaining in the grafts are the most important parameters for evaluating the transplantation effect. Three days and seven days after frozen-thawed ovarian tissue transplantation, five rabbits in each group were selected to obtain grafts for HE staining, and the number of primordial follicles in each group was counted under a microscope to measure the density of primordial follicles in each graft.
[0101] Three days after transplantation, the primordial follicle density of comparison example 1 and comparison example 2 was 5.55±0.52 and 7.53±0.52, respectively, and there was no statistical difference between the two groups (P>0.05); the primordial follicle density of Example 2 was 19.21±2.01, which was significantly higher than that of comparison examples 1 and 2, and the difference was statistically significant (P<0.05).
[0102] Seven days after transplantation, the primordial follicle density of control group 1 was 5.89±2.20, which was significantly lower than that of control group 2 (21.45±9.06) and control group 5 (36.11±2.01), and the difference was statistically significant (P<0.05).
[0103] Calculation of the apoptosis rate of primordial follicles 3 days and 7 days after transplantation
[0104] In order to determine the apoptosis of the remaining primordial follicles, the surviving grafts in each group were subjected to Tunel immunofluorescence staining, and the apoptosis rate of primordial follicles in each group was calculated 3 days and 7 days after ovarian tissue transplantation.
[0105] Three days after transplantation, the apoptosis rates of primordial follicles in comparative example 1, comparative example 2 and example 2 were 0.09±0.014, 0.08±0.021 and 0.06±0.014, respectively, and there was no significant difference among the three groups (P>0.05).
[0106] Seven days after transplantation, the apoptosis rates of primordial follicles in Comparative Example 1, Comparative Example 2 and Example 2 were 0.12±0.013, 0.10±0.008 and 0.09±0.012, respectively, and there was no significant difference among the three groups (P>0.05).
[0107] This document uses specific examples to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only used to help understand the technical solution and its core idea of the present application. Ordinary technicians in this field should understand that they can still modify the technical solutions recorded in the aforementioned embodiments, or replace some of the technical features therein with equivalents; and these modifications or replacements do not make the essence of the corresponding technical solution deviate from the scope of the technical solution of the embodiments of the present application.
Claims
1. A composition for ovarian transplantation, characterized in that: Includes antioxidant peptides and colony stimulating factors.
2. The composition according to claim 1, characterized in that The ratio of colony stimulating factor to antioxidant peptide is 1mL:10~100mg.
3. The composition according to claim 2, characterized in that The ratio of colony stimulating factor to antioxidant peptide is 1mL:50mg.
4. The composition according to claim 1, characterized in that The colony stimulating factor is selected from any one of macrophage colony stimulating factor, granulocyte macrophage colony stimulating factor and granulocyte colony stimulating factor.
5. The composition according to claim 4, characterized in that The antioxidant peptide is SS31.
6. The composition according to claim 5, characterized in that The composition includes granulocyte macrophage colony stimulating factor and SS31.
7. A method for preparing a composition for ovarian transplantation, characterized in that: The preparation method of the composition comprises: fusing the antioxidant peptide and the colony stimulating factor to prepare the composition according to any one of claims 1 to 6.
8. The preparation method according to claim 7, characterized in that: The fusion temperature is 30-40°C.
9. A use of a composition for ovarian transplantation, characterized in that: The composition according to any one of claims 1 to 6 is used for ovarian transplantation.
10. A method for tracing a composition for ovarian transplantation, characterized in that: The composition according to any one of claims 1 to 6 is traced with rhodamine.
Citation Information
Patent Citations
Peptide modified chitosan hydrogel composition and preparation method thereof
CN113304308A
Application of mitochondrial polypeptide Humanin and analogue in preparation of medicine for protecting ovarian function
CN115227805A
